| SC 13G/A | 2024-02-14 | LYTTON LAURENCE W | GYRE THERAPEUTICS, INC. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2024-01-24 | GNI Group Ltd. | GYRE THERAPEUTICS, INC. | 73,313,885 | 85.3% | EDGAR |
| SC 13D/A | 2023-11-27 | GNI Group Ltd. | GYRE THERAPEUTICS, INC. | 73,313,885 | 85.4% | EDGAR |
| SC 13D/A | 2023-11-01 | GNI Group Ltd. | GYRE THERAPEUTICS, INC. | 73,313,885 | 85.4% | EDGAR |
| SC 13D/A | 2023-10-31 | GNI Group Ltd. | GYRE THERAPEUTICS, INC. | 6,266,521 | 16.5% | EDGAR |
| SC 13G/A | 2023-02-14 | ORBIMED ADVISORS LLC | CATALYST BIOSCIENCES, INC. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | Nantahala Capital Management, LLC | CATALYST BIOSCIENCES, INC. | 438,055 | 1.4% | EDGAR |
| SC 13G/A | 2023-02-13 | LYTTON LAURENCE W | CATALYST BIOSCIENCES, INC. | 2,667,333 | 7.1% | EDGAR |
| SC 13G/A | 2023-02-13 | RENAISSANCE TECHNOLOGIES LLC | CATALYST BIOSCIENCES, INC. | 1,186,986 | 3.1% | EDGAR |
| SC 13D | 2023-01-05 | GNI Group Ltd. | CATALYST BIOSCIENCES, INC. | 6,266,521 | 16.6% | EDGAR |
| SC 13D/A | 2022-10-07 | SINGER JULIAN D. | CATALYST BIOSCIENCES, INC. | 1,082,400 | 3.4% | EDGAR |
| SC 13D/A | 2022-09-22 | JEC II Associates, LLC | CATALYST BIOSCIENCES, INC. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2022-08-19 | SINGER JULIAN D. | CATALYST BIOSCIENCES, INC. | 2,247,442 | 7.1% | EDGAR |
| SC 13D/A | 2022-08-03 | SINGER JULIAN D. | CATALYST BIOSCIENCES, INC. | 2,247,442 | 7.1% | EDGAR |
| SC 13D/A | 2022-08-01 | JEC II Associates, LLC | CATALYST BIOSCIENCES, INC. | 1,550,000 | 4.9% | EDGAR |
| SC 13D/A | 2022-07-22 | SINGER JULIAN D. | CATALYST BIOSCIENCES, INC. | 2,247,442 | 7.1% | EDGAR |
| SC 13D/A | 2022-07-01 | JEC II Associates, LLC | CATALYST BIOSCIENCES, INC. | 1,550,000 | 4.9% | EDGAR |
| SC 13D | 2022-06-21 | JEC II Associates, LLC | CATALYST BIOSCIENCES, INC. | 1,550,000 | 4.9% | EDGAR |
| SC 13D/A | 2022-06-17 | SINGER JULIAN D. | CATALYST BIOSCIENCES, INC. | 2,014,832 | 6.4% | EDGAR |
| SC 13D/A | 2022-05-25 | SINGER JULIAN D. | CATALYST BIOSCIENCES, INC. | 2,014,832 | 6.4% | EDGAR |